$3.74
0.020.54%
Last update: Nov 11, 4:00 PM
Fulcrum Therapeutics Inc
FULCNASDAQ
Fulcrum Therapeutics fell 55.3% from $8.36 to $3.74, behind the S&P 500's +11.2%. Its worst day was Jun 2 (−51.1%), and its low came Jun 2 at $3.14.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Fulcrum Therapeutics shares rose 18.3%, while the S&P 500 rose 0.4%.
+18.3% · S&P 500 +0.4%
Fulcrum Therapeutics closed at its highest level of the year, 74.6% above where the year started.
+12.4% · S&P 500 −0.1%
Story events cover the past 12 months · Times ET
EPS of $-0.31 beat the $-0.31 estimate on $0.00 revenue.
−21.2% · S&P 500 +0.7%
Fulcrum Therapeutics shares rose 16.6%, while the S&P 500 rose 2.9%.
+16.6% · S&P 500 +2.9%
EPS of $-0.25 beat the $-0.30 estimate on $0.00 revenue.
−1.5% · S&P 500 +0.2%
Fulcrum Therapeutics closed at its lowest level of the year, 62.4% below where the year started.
−51.1%, the year's worst day, on 33M shares, the year's heaviest volume · S&P 500 +0.1%
EPS of $-0.34 missed the $-0.22 estimate on $0.00 revenue.
−3.8% · S&P 500 +0.7%
Where it ended: a close of $3.74 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.11).
Nothing in the past 12 months.
All FULC dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for FULC and SPY from Benzinga historical bars. Not investment advice.
